Purpose: To evaluate the feasibility of percutaneous isolated pancreatic perfusion (PIPP) chemotherapy from fundamental experiments to clinical applications.
Methods: We conducted two major experiments for PIPP using 32 pigs. In the first experiment, pharmacologic, histopathologic, and chronological laboratory studies were performed to determine the optimal infusion rate. In the second experiment, 17 pigs underwent PIPP with contrast medium, and the percent enhanced volume to the whole pancreas (%eV) was quantitated at 3 infusion rates of 12, 24, and 36 mL/min by MDCT arteriography. Additional experiments underwent a revised PIPP without and with balloon occlusion of the anterior mesenteric artery (AMA), and the %eV was compared.
Results: In the first study, the optimal infusion rate of 40 mL/min was selected in terms of histopathological safety. The median pancreatic-to-systemic exposure ratios were 71.8 for C-max and 54.8 for the area under the curve. All laboratory data remained normal or returned to pretreatment levels within 1 week. In the second study, without AMA occlusion, high infusion rates significantly increased the enhancement volume. With AMA occlusion, the median %eVs were 92.8%, 95.4%, and 98.5%, respectively, significantly larger than the corresponding areas without AMA occlusion (P = 0.031).
Conclusion: PIPP is feasible and may enable either partial or complete drug delivery to the pancreas as required. Based on experimental results, we started to perform PIPP for patients with stage IV pancreatic cancer.
View full abstract